SFFS
PBM icon

Stonehage Fleming Financial Services’s Psyence Biomedical PBM Stock Holding History

Stonehage Fleming Financial Services’s Portfolio PBM Stock Details PBM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272 Hold
89
– – ﹤0.01% 212
2026
Q1 		$218 Sell
89
-1
-1% -$3 ﹤0.01% 224
2025
Q4 		$422 Hold
90
– – ﹤0.01% 219
2025
Q3 		$1.79K Hold
90
– – ﹤0.01% 214
2025
Q2 		$2.99K Hold
90
– – ﹤0.01% 205
2025
Q1 		$2.69K Buy
+90
New +$5.73K ﹤0.01% 183
2024
Q4 		– Sell
-22
Closed -$8.05K – 240
2024
Q3 		$8.05K Buy
+22
New +$29.8K ﹤0.01% 205

Other funds holding PBM

PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CJ
Caitlin John Brighton, Michigan $183M AUM 30.77% 1-Year Est. Return

Stonehage Fleming Financial Services's PBM Position: Q2 2026 in Review

Stonehage Fleming Financial Services held its Psyence Biomedical (PBM) position steady in Q2 2026 at 89 shares worth $272. The position accounts for ﹤0.01% of the portfolio, ranked #212.

Stonehage Fleming Financial Services first reported a position in PBM in Q3 2024 and has held it in 7 quarters since. The position peaked at $8.05K in Q3 2024. 9 funds tracked by Wall St. Rank hold PBM as of Q2 2026.

  • Stonehage Fleming Financial Services held 89 shares of Psyence Biomedical worth $272 as of Q2 2026.
  • Stonehage Fleming Financial Services left its Psyence Biomedical share count unchanged in Q2 2026.
  • Psyence Biomedical made up ﹤0.01% of Stonehage Fleming Financial Services's portfolio in Q2 2026, its #212 holding.
  • Stonehage Fleming Financial Services first reported a position in Psyence Biomedical in Q3 2024 and has held it in 7 quarters since.
  • Stonehage Fleming Financial Services's Psyence Biomedical position peaked at $8.05K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Psyence Biomedical as of Q2 2026.

Based on Stonehage Fleming Financial Services's 13F filing for Q2 2026, filed 17 Aug 2026.